EP-104GI - (RESOLVE)

Aug. 13, 2026: Eupraxia Pharmaceuticals (NASDAQ/TSX: EPRX) reported a new analysis from the Phase 1b/2a RESOLVE trial of EP-104GI in eosinophilic esophagitis (EoE), highlighting improvements in swallowing-related symptoms and continued tolerability.

In Cohorts 7-9 (20 injections; total dose 80-160 mg), moderate or severe odynophagia fell from 62% at baseline to 31% at weeks 2-12 and 25% at weeks 24, 36 and 52; patients with no odynophagia increased from 15% at baseline to 50% at week 52. Severe odynophagia was 23% at baseline and 0% at weeks 24 and 52. Moderate or severe dysphagia fell from 77% at baseline to 54% at week 12 and 25% at weeks 24 and 52; severe dysphagia declined from 31% at baseline to 0% at weeks 24 and 52.

Safety remained favorable: across both portions of RESOLVE, more than 130 patients have received EP-104GI or placebo across more than 2,000 injection sites, with no treatment-emergent or procedure-related serious adverse events reported.

The Phase 2b randomized, placebo-controlled RESOLVE study is recruiting 120 mg and 160 mg dose cohorts, with an interim readout expected in Q4 2026. Additional open-label Phase 1b/2a data are planned in the coming months.